Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 7 PH6 versus TRAVASOL 8 5 W O ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 7 PH6 versus TRAVASOL 8 5 W O ELECTROLYTES.
AMINOSYN 7% (PH6) vs TRAVASOL 8.5% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and metabolic processes, providing essential and non-essential amino acids for tissue repair and maintenance.
TRAVASOL 8.5% W/O ELECTROLYTES provides amino acids for protein synthesis, serving as a source of nitrogen and essential amino acids to support anabolism and prevent catabolism in patients unable to tolerate oral or enteral nutrition.
AminoSyn 7% (pH 6) is administered intravenously as a component of parenteral nutrition. The typical adult dose is 1.0-1.5 g amino acids/kg/day, infused at a rate not exceeding 0.1 g amino acids/kg/hour. The infusion rate and volume are determined by the patient's metabolic needs, clinical status, and concurrent dextrose and lipid administration.
Intravenous infusion; 500 mL to 1 L per day, administered at a rate of 100-200 mL/hour. Dosage depends on protein and calorie requirements, typically 0.8-1.5 g/kg/day of amino acids.
None Documented
None Documented
The elimination half-life of individual amino acids varies, typically 0.5-2 hours for most, reflecting rapid incorporation into metabolic pools. For total amino acid mixture, functional half-life is approximately 1-2 hours in patients with normal hepatic and renal function.
Not applicable as a single value; amino acids have variable half-lives (minutes to hours) depending on individual metabolic demand and plasma concentration; continuous infusion achieves steady state rapidly.
Amino acids in Aminosyn 7% (pH6) are primarily metabolized; excess nitrogen is excreted renally as urea. Approximately 80-90% of infused amino acids are utilized for protein synthesis or metabolized; remaining nitrogen is eliminated as urea via kidneys. Biliary and fecal elimination are negligible.
Primarily eliminated via metabolic pathways (hepatic deamination and transamination) with nitrogenous waste excreted renally as urea; negligible biliary/fecal excretion of unchanged amino acids.
Category C
Category C
Amino Acid Solution
Amino Acid Solution